The bulls are sharpening their horns in sweet anticipation of Vanda Pharmaceuticals' (VNDA) upcoming Advisory Committee Meeting with the FDA for tasimelteon's New Drug Application (NDA). Tasimelteon is a circadian regulator in development as an indication for Non-24Hr disorder in the totally blind.
Last December, Vanda reported positive Phase III data for tasimelteon, causing the stock to surge 166% year-to-date. Adding fuel to the fire, the FDA recently agreed to bestow upon tasimelteon a highly coveted "Priority Review". The drug is thus set for an Advisory Committee hullabaloo on November 14th, with a target PDUFA date of January 31, 2014. With peak sales projected to top $500 M per year for a company with a sub $300...
Only subscribers can access this article, which is part of the PRO research library covering 3,770 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: